Yanjun Wang
- Mast cells and histamine
- Synthesis and Catalytic Reactions
- Immune cells in cancer
- Cancer Research and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Immune Cell Function and Interaction
- Inflammatory mediators and NSAID effects
- Amino Acid Enzymes and Metabolism
- Cancer Immunotherapy and Biomarkers
AstraZeneca (United States)
2023
Abstract Antitumor immunity can be hampered by immunosuppressive mechanisms in the tumor microenvironment, including recruitment of arginase (ARG) expressing myeloid cells that deplete l-arginine essential for optimal T-cell and natural killer cell function. Hence, ARG inhibition reverse immunosuppression enhancing antitumor immunity. We describe AZD0011, a novel peptidic boronic acid prodrug to deliver an orally available, highly potent, inhibitor payload (AZD0011-PL). demonstrate...
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 1</p>
<div>Abstract<p>Anti-tumor immunity can be hampered by immunosuppressive mechanisms in the tumor microenvironment including recruitment of arginase (ARG) expressing myeloid cells which deplete L-arginine essential for optimal T cell and natural killer function. Hence, ARG inhibition reverse immunosuppression enhancing anti-tumor immunity. We describe AZD0011, a novel peptidic boronic acid prodrug to deliver an orally available, highly potent, inhibitor payload (AZD0011-PL)....
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 2</p>
<div>Abstract<p>Antitumor immunity can be hampered by immunosuppressive mechanisms in the tumor microenvironment, including recruitment of arginase (ARG) expressing myeloid cells that deplete l-arginine essential for optimal T-cell and natural killer cell function. Hence, ARG inhibition reverse immunosuppression enhancing antitumor immunity. We describe AZD0011, a novel peptidic boronic acid prodrug to deliver an orally available, highly potent, inhibitor payload (AZD0011-PL)....
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 4</p>